An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach
Authors:
Open Access
- 3 August 2020
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Abstract
The optimal post-treatment surveillance strategy that can detect early recurrence of a cancer within limited visits remains unexplored. Here we adopt nasopharyngeal carcinoma as the study model to establish an approach to surveillance that balances the effectiveness of disease detection versus costs. A total of 7,043 newly-diagnosed patients are grouped according to a clinic-molecular risk grouping system. We use a random survival forest model to simulate the monthly probability of disease recurrence, and thereby establish risk-based surveillance arrangements that can maximize the efficacy of recurrence detection per visit. Markov decision-analytic models further validate that the risk-based surveillance outperforms the control strategies and is the most cost-effective. These results are confirmed in an external validation cohort. Finally, we recommend the risk-based surveillance arrangement which requires 10, 11, 13 and 14 visits for group I to IV. Our surveillance strategies might pave the way for individualized and economic surveillance for cancer survivors.Keywords
This publication has 32 references indexed in Scilit:
- Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineationChinese Journal of Cancer, 2012
- Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapyEuropean Journal of Cancer, 2012
- Pretreatment Lifestyle Behaviors as Survival Predictors for Patients with Nasopharyngeal CarcinomaPLOS ONE, 2012
- To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic areaEuropean Journal of Cancer, 2012
- Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trialThe Lancet Oncology, 2012
- Cancer of the esophagus and esophagogastric junctionCancer, 2010
- Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225Journal of Clinical Oncology, 2009
- Random survival forestsThe Annals of Applied Statistics, 2008
- Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institutionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006